secwatch.observer — SEC 8-K summary
======================================

Issuer:     Phathom Pharmaceuticals, Inc. (PHAT)
CIK:        0001783183
Form:       8-K
Filed at:   2025-10-27T23:59:59+00:00
Accession:  0001193125-25-250611
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Phathom publishes Phase 3 NERD data showing VOQUEZNA improves nocturnal GERD symptoms
--------------------------------------------------------------------------------

- At week 4, VOQUEZNA 10 mg and 20 mg achieved 59.9% and 56.4% heartburn-free nights vs 43.3% placebo (nominal p<0.0001).
- Median heartburn-free nights: 70.4% (10 mg), 71.0% (20 mg), 45.5% (placebo) over 4 weeks.
- Separation from placebo observed after first dose: 45.3% (10 mg) and 52.4% (20 mg) heartburn-free night vs 32.1% placebo.
- Symptom relief sustained through 20-week active extension; median heartburn-free nights remained above 70%.
- VOQUEZNA generally well tolerated; most common AEs (≤5%) included URI, sinusitis, influenza, UTI, nausea.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1783183/000119312525250611/0001193125-25-250611-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1783183/000119312525250611/d62248d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-250611

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer